Quoin Pharmaceuticals Ltd. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Quoin Pharmaceuticals Ltd. (Israeli biotech, ~$5.4M market cap) entered into a sales agreement with Leerink Partners LLC on November 4, 2026 to conduct an at-the-market (ATM) offering of American Depositary Shares (ADSs), each representing 35 ordinary shares. Maximum offering size: $11,000,000 gross proceeds, representing the full amount eligible under Form S-3 General Instruction I.B.6. Leerink receives 3.0% commission on gross proceeds. Registration Statement (File 333-299668) became effective November 4, 2026. Company retains sole discretion to initiate sales via Placement Notices; Agent has no obligation to purchase and uses best efforts to sell at market prices.
Why this rating
ATM offering of $11M is ~204% of company's $5.4M market cap—transformational if fully deployed. Provides liquidity optionality but carries dilution risk; timing/execution uncertain. Significant for capital raising capacity relative to size.
Extracted items
- 2.02 results / earnings
- 7.01 Reg FD disclosure
Price action (we called it positive)
before filing · preread $4.02 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.